Fulcrum Therapeutics, Inc. (FULC) compared with its closest peers (RNAC, TRDA, TTRX, CAMP, ELDN). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | $294.84M | -1.4 |
| Entrada Therapeutics, Inc. (TRDA) | $294.65M | -3.0 |
| Turn Therapeutics Inc. (TTRX) | $282.84M | -33.6 |
| CAMP4 Therapeutics Corporation (CAMP) | $280.51M | -2.3 |
| Eledon Pharmaceuticals, Inc. (ELDN) | $279.13M | -2.9 |
| ALX Oncology Holdings Inc. (ALXO) | $273.84M | -0.6 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | $271.93M | -0.7 |
| Immuron Limited (IMRN) | $271.39M | — |
| Q32 Bio Inc. (QTTB) | $270.79M | 1.4 |
| vTv Therapeutics Inc. (VTVT) | $270.06M | 119.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
FULC overview · FULC earnings · FULC financials · FULC KPIs · FULC investor relations · FULC ownership · FULC filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.